Voyager Therapeutics (VYGR) Reports Q2 Loss of $0.37/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
August 11, 2016 7:05 AM EDTVY-AADC01 Phase 1b Study for Advanced Parkinsons Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016
Pipeline Advances with Selection of Lead Clinical Candidates for Multiple Pipeline Programs by Late 2016 or Early 2017
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today reported its second quarter 2016 financial results and highlighted recent pipeline and corporate achievements,... More
Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson’s Disease
August 9, 2016 7:05 AM EDTCAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced dosing of the first patient in the third cohort of the ongoing Phase 1b open-label trial of VY-AADC01 in patients with advanced Parkinsons disease following a recent meeting of the trials data and safety monitoring board.Â
We are pleased with the progress of this ongoing Phase 1b trial and the initiation of the planned third... More
